Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carrelizumab plus chemotherapy with or without radiotherapy in extensively metastatic solid tumors
ChiCTR2200060637Phase 2Not yet recruiting
- Sponsor
- Shandong Provincial Hospital Affiliated to Shandong First Medical University
- Start
- Mar 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of camrelizumab in solid tumor (2 arms), sponsored by Shandong Provincial Hospital Affiliated to Shandong First Medical University. Primary endpoints: Objective response rate and Progression-free survival. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
camrelizumab
03
Conditions
solid tumor
Beyond the preview
Go deeper on ChiCTR2200060637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060637.